Medication persistence for psoriatic arthritis in a Brazilian real-world setting

AIM: To evaluate the persistence of biological (TNF inhibitor [anti-TNF]) and synthetic (conventional synthetic disease-modifying antirheumatic drugs [csDMARDs]) antirheumatic agents for psoriatic arthritis and their associated factors. METHODS: A historical cohort was developed. Persistence and ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Ribeiro da Silva, Michael Ruberson, Ribeiro dos Santos, Jéssica Barreto, Maciel Almeida, Alessandra, Itria, Alexander, Maria Kakehasi, Adriana, Alvares Teodoro, Juliana, de Assis Acurcio, Francisco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Science Ltd 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391629/
https://www.ncbi.nlm.nih.gov/pubmed/30820348
http://dx.doi.org/10.4155/fsoa-2018-0101
Descripción
Sumario:AIM: To evaluate the persistence of biological (TNF inhibitor [anti-TNF]) and synthetic (conventional synthetic disease-modifying antirheumatic drugs [csDMARDs]) antirheumatic agents for psoriatic arthritis and their associated factors. METHODS: A historical cohort was developed. Persistence and associated factors were evaluated at 6 and 12 months. RESULTS: A total of 161 patients were included. The anti-TNF treatment presented higher persistence as compared with csDMARDs at 6 (83.4 vs 50.8%; p < 0.05) and 12 months (66.4 vs 35.6%; p < 0.05). From anti-TNFs, adalimumab and etanercept presented similar persistence, along with leflunomide and methotrexate among the csDMARDs. The factors associated with non-persistence with regard to anti-TNF agents were female sex and use of infliximab. CONCLUSION: Anti-TNF agents are important therapeutic alternatives and present lower rates of discontinuation as compared with csDMARDs.

Ejemplares similares